Loading stock data…
RPID
$2.53+0.13 (+5.42%)
Market ClosedLast close May 1
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rapid Micro Biosystems, Inc. in the Healthcare sector is trading at $2.53. The stock is currently near its 52-week low of $2.01, remaining 23.3% below its 200-day moving average. Technical signals show neutral RSI of 65 and bullish MACD crossover, explaining why RPID maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 65) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.53
Potential Upside
5%
Whystock Fair Value$2.66
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switze...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$102.98M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.60
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-133.39%
Volume
Today's trading volume
64,783
Recent News
Pioneer Power Solutions And 2 Other Penny Stocks Worth Watching
In the last week, the U.S. market has stayed flat, but over the past 12 months, it has risen by 30%, with earnings expected to grow by 16% per annum in the coming years. Amidst these conditions, identifying stocks with solid fundamentals and growth potential is crucial for investors looking to capitalize on market opportunities. Penny stocks may be an outdated term, but they still represent a valuable investment area; when backed by strong financials and balance sheet strength, these smaller...
White Brook Capital Shared Insights on Rapid Micro Biosystems (RPID)
White Brook Capital Partners, an investment management firm, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter indicated that the first quarter of 2026 was a turnaround period. During this quarter, US military actions against Iran and developments in AI dominated economic discussions. These military interventions created a […]
What Makes Rapid Micro Biosystems (RPID) a New Buy Stock
Rapid Micro Biosystems (RPID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rapid Micro Biosystems Eyes $37M-$41M 2026 Revenue as Growth Direct Day Draws Record Crowd
Rapid Micro Biosystems (NASDAQ:RPID) executives highlighted the company’s effort to modernize microbial quality control in pharmaceutical manufacturing, discussed recent customer engagement activity, and outlined key variables behind its 2026 outlook during a Q&A session hosted by KeyBanc’s Anna
Rapid Micro Biosystems Inc (RPID) Q4 2025 Earnings Call Highlights: Record Revenue Growth Amid ...
Despite a 37% revenue surge, Rapid Micro Biosystems Inc (RPID) faces margin pressures and increased net loss, while strategic partnerships and system placements show promising growth.